Esperion Therapeutics, Inc. (ESPR)
Stock Price:
$27.55 USD
0.21 (0.77%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $27.25 -0.30 (-1.09%) Nov 24, 5:20 PM
Key Info
| Market Cap |
768.00M |
| Revenue (ttm) |
218.89M |
| Net Income (ttm) |
-101.02M |
| Shares Out |
27.88M |
| EPS (ttm) |
-3.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$27.55 |
| Previous Close |
$27.34 |
| Change ($) |
0.21 |
| Change (%) |
0.77% |
| Day's Open |
27.36 |
| Day's Range |
27.30 - 28.47 |
| Day's Volume |
1,048,181 |
| 52-Week Range |
23.90 - 76.98 |
More Stats
| Market Cap |
768.00M |
| Enterprise Value |
730.16M |
| Earnings Date (est) |
Feb 24, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.88M |
| Float |
23.01M |
| EPS (basic) |
-3.70 |
| EPS (diluted) |
-3.66 |
| FCF / Share |
-2.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.06M |
| Short Ratio |
20.09 |
| Short % of Float |
43.72% |
| Beta |
1.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.51 |
| PB Ratio |
86.52 |
| Revenue |
218.89M |
| Operating Income |
-84.79M |
| Net Income |
-101.02M |
| Free Cash Flow |
-67.49M |
| Net Cash |
37.84M |
| Net Cash / Share |
1.36 |
| Gross Margin |
-12.45% |
| Operating Margin |
-38.74% |
| Profit Margin |
-46.20% |
| FCF Margin |
-30.83% |
| ROA |
-20.94% |
| ROE |
-260.79% |
| ROIC |
-67.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (11)
| Buy |
7 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$75.91*
(175.54% upside)
Low
32.0
Current: $27.55
High
191.0
Target: 75.91
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 148 | - | - | - | - | - | - | - | - |
| Gross Profit | 148 | - | - | - | - | - | - | - | - |
| Operating Income | -93.10 | -205 | -169 | -76.15 | -50.04 | -36.22 | -22.76 | -10.20 | -10.16 |
| Net Income | -97.17 | -202 | -167 | -74.98 | -49.78 | -36.38 | -26.09 | -11.74 | -10.82 |
| Shares Outstanding | 27.09 | 26.75 | 23.93 | 22.54 | 22.02 | 16.37 | 7.89 | 0.32 | 0.30 |
| Earnings Per Share | -3.59 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -3.31 | -36.31 | -36.22 |
| Operating Cash Flow | -70.34 | -149 | -131 | -47.73 | -38.16 | -32.02 | -18.11 | -10.81 | -9.07 |
| Capital Expenditures | -0.95 | -0.15 | -0.02 | -0.09 | -0.30 | -0.86 | 0.17 | - | 0.01 |
| Free Cash Flow | -71.29 | -149 | -131 | -47.82 | -38.46 | -32.88 | -17.94 | -10.81 | -9.06 |
| Cash & Equivalents | 202 | 136 | 200 | 212 | 212 | 106 | 60.06 | 6.51 | 1.57 |
| Total Debt | 134 | - | 1.05 | 2.73 | 4.29 | 4.87 | - | 22.77 | 6.90 |
| Net Cash / Debt | 67.60 | 136 | 199 | 209 | 208 | 101 | 60.06 | -16.26 | -5.33 |
| Assets | 214 | 143 | 278 | 245 | 296 | 143 | 78.29 | 7.31 | 2.18 |
| Liabilities | 194 | 64.33 | 33.14 | 16.61 | 8.31 | 9.72 | 4.20 | 24.70 | 8.24 |
| Book Value | 19.95 | 79.12 | 245 | 229 | 287 | 134 | 74.09 | -41.36 | -30.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Esperion Therapeutics, Inc. |
| Country |
United States |
| Employees |
193 |
| CEO |
Tim M. Mayleben |
Stock Information
| Ticker Symbol |
ESPR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ESPR |
| IPO Date |
June 26, 2013 |
Description
Esperion Therapeutics, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.